About This Reference Desk

What Living Water Peptides is

Living Water Peptides reads the published research on two molecules at the center of longevity and cellular health — NAD+ and MOTS-c, with NAD+ leading — and keeps it the way you would keep an almanac: entries in plain language, each anchored to a numbered PubMed citation, noting what a molecule was actually studied for, in which species, and how far the evidence honestly carries. This literature moves fast and is easy to overstate, so the almanac's whole job is to make it legible.

The frame throughout is cellular energetics — both molecules read through mitochondrial biology and the metabolism of aging. NAD+ is the coenzyme whose slow age-related fall powers the whole precursor-supplement field; MOTS-c is a peptide encoded inside the mitochondrion that signals outward to the nucleus when the cell is under metabolic strain. Two different molecular routes into one question: what fails in the aging cell's energy machinery. Each molecule gets its own entry, a side-by-side comparison page sets them against each other, and one shared reference list gathers every source in the almanac.

How it is compiled

Three habits shape what lands in the almanac.

First, nothing appears without a source in the peer-reviewed record. Each research claim carries a numbered citation — PubMed-indexed papers and reviews, with a DOI or link — gathered on the references page. A finding drawn from a review is marked as coming from a review, and the details that decide evidential weight (effect size, randomized versus observational, human versus animal, sample size) are written out rather than smoothed away.

Second, the evidence is reported at its true strength. Doses are described in the species and route in which they were studied — for example, "oral NMN at 600 mg/day in middle-aged adults" or "5 mg/kg subcutaneously in mice" — never scaled up from animals or offered as a human recommendation. Where evidence is preclinical, rests on a surrogate endpoint rather than a clinical outcome, or where a 2025 authoritative review has specifically called out the gap between blood-level changes and clinical benefit, this page says so.

Third, the entries talk to each other. Because the same mechanisms — AMPK activation, sirtuin function, mitochondrial signaling — surface under both molecules, the pages cross-link so a reader can trace one pathway from NAD+ across to MOTS-c.

What it is not

The almanac is not a store, not a clinic, and not a place to get medical advice. Nothing here is sold, supplied, sourced, or brokered — no molecule, supplement, or research chemical — and there is no affiliate or referral tie to any vendor. No one on it examines patients, names a diagnosis, or prescribes. It sets no dose, schedule, or route for any person, and it never dresses an animal-study dose up as something a human should take.

The molecules discussed here occupy different regulatory categories: NAD+ precursors are dietary supplements with contested marketplace status in some cases; MOTS-c is an unapproved research chemical prohibited in sport. Neither is a treatment for any condition. Readers interested in any health concern described in the underlying research should consult a licensed clinician operating within their own jurisdiction, working with regulated, evidence-based options. What this almanac offers is a steady, sourced reading of the published literature — nothing more, and nothing it pretends to be.